About
Tavira Therapeutics develops a modular, post-manufacture enzymatic platform to modify adeno-associated virus (AAV) vectors by attaching targeting molecules, aiming to improve tissue specificity and reduce off-target effects in gene therapies.
Explore Tavira Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.